Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482728 · ClinicalTrials.gov registry record · Early Phase 1
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer
A Early Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT01482728: Completed Early Phase 1 study, sponsored by University of Virginia.
NCT01482728 is a Early Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 12 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01482728, a Early Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the investigators can measure inhibition of a protein, Src (named for Sarcoma), in tissue and blood in patients with a diagnosis of endometrial cancer. Dasatinib is a drug that blocks the activity of an important protein in cancer cells called Src. The investigators can measure the blocking of Src in the bloodstream. However, the investigators do not know if measures in the bloodstream reflect blockage of Src in cancer tissue. The investigators are doing this study to try and see if the investigators can match what the investigators see in cancer tissue to what the investigators see in the bloodstream. the investigators hope that in the future, the investigators can use blood to measure protein inhibition by dasatinib instead of asking patients to undergo repeat biopsies.
Primary Outcome
In this study the change in levels of SFK protein activity in both tissue and blood will represent the measured pharmacodynamic response.
Interventions
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-12 |
| Phase | Early Phase 1 |
What the finished NCT01482728 record still lists
NCT01482728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Dasatinib is the first listed.
NCT01482728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01482728 about?
NCT01482728 is a clinical study titled "Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer". The purpose of this study is to see if the investigators can measure inhibition of a protein, Src (named for Sarcoma), in tissue and blood in patients with a diagnosis of endometrial cancer. Dasatinib is a drug that blocks the activity of an important protein in cancer cells called Src. The investig...
What is the current status of trial NCT01482728?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2012-01. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01482728?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT01482728?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01482728's enrollment target sits among peer trials
12 1530th of 2000 higher than 401 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia